Get the Stockscreener App
5.69
6.36%
0.34
After Hours:
5.72
0.03
+0.53%
Ardelyx Inc Stock (ARDX) Latest News
Ardelyx CEO Michael Raab sells $134,482 in stock - Investing.com
Rubric Capital Management LP Buys 1,243,606 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
Propel Bio Management LLC Has $7.38 Million Position in Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It (NASDAQ:ARDX) - Seeking Alpha
Principal Financial Group Inc. Sells 336,014 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
Insider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells 31,980 Shares of Stock - MarketBeat
Ardelyx's regulatory officer sells $23,689 in stock By Investing.com - Investing.com Australia
Ardelyx CEO Michael Raab sells $153,328 in common stock By Investing.com - Investing.com Nigeria
Ardelyx executive sells $33,782 in stock - Investing.com India
Ardelyx executive sells $33,782 in stock By Investing.com - Investing.com South Africa
Ardelyx's regulatory officer sells $23,689 in stock - Investing.com India
Ardelyx, Inc. (NASDAQ:ARDX) CFO Sells $25,195.40 in Stock - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Insider Laura A. Williams Sells 7,366 Shares - MarketBeat
Ardelyx chief development officer sells $34,443 in stock By Investing.com - Investing.com Nigeria
Ardelyx chief medical officer sells $35,316 in stock By Investing.com - Investing.com Nigeria
Ardelyx CFO Justin Renz sells $25,219 in stock By Investing.com - Investing.com South Africa
Ardelyx CFO Justin Renz sells $25,219 in stock - Investing.com India
Ardelyx chief medical officer sells $35,316 in stock - Investing.com
Ardelyx chief development officer sells $34,443 in stock - Investing.com
Ardelyx Independent Chairman of the Board Acquires 18% More Stock - Simply Wall St
Ardelyx, Inc Announces Executive Changes - Marketscreener.com
Shareholders of Ardelyx, Inc. Should Contact The Gross Law Firm - GuruFocus.com
Class Action Filed Against Ardelyx, Inc. (ARDX) Seeking Recovery for InvestorsContact Levi & Korsinsky - GuruFocus.com
ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com
Ardelyx, Inc. Sued for Securities Law ViolationsContact the D - GuruFocus.com
Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop - MSN
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Ardelyx Executives to Present at Piper Sandler Healthcare Conference | ARDX Stock News - StockTitan
Jefferies optimistic on Ardelyx stock as management navigates reimbursement changes - Investing.com
High Growth Tech Stocks To Explore In November 2024 - Yahoo Finance
Ardelyx appoints new principal accounting officer - Investing.com
US Penny Stocks To Monitor In November 2024 - Simply Wall St
Ardelyx, Inc. (NASDAQ:ARDX) Short Interest Up 5.1% in October - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Ardelyx (NASDAQ:ARDX) Shares Gap UpTime to Buy? - MarketBeat
Janus Henderson Group PLC's Strategic Reduction in Ardelyx Inc H - GuruFocus.com
Director David Mott Acquires 215,868 Shares of Ardelyx Inc (ARDX) - GuruFocus.com
Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability (NASDAQ:ARDX) - Seeking Alpha
HC Wainwright Has Bearish Forecast for Ardelyx Q1 Earnings - MarketBeat
Ardelyx (NASDAQ:ARDX) Rating Lowered to “Neutral” at HC Wainwright - Defense World
Ardelyx shares downgraded amid sales concerns for XPHOZAH By Investing.com - Investing.com Australia
Ardelyx (NASDAQ:ARDX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Ardelyx shares downgraded amid sales concerns for XPHOZAH - Investing.com India
Ardelyx (NASDAQ:ARDX) Lowered to Neutral Rating by HC Wainwright - MarketBeat
Ardelyx chief development officer sells shares worth $165,743 - Investing.com India
David P. Rosenbaum Sells 27,171 Shares of Ardelyx, Inc. (NASDAQ:ARDX) Stock - MarketBeat
Ardelyx chief development officer sells shares worth $165,743 By Investing.com - Investing.com Australia
Ardelyx Beats Q3 Sales Estimates, Shares Climb - MSN
Ardelyx Loses Bid to Block HHS Classification of Kidney Drug - Bloomberg Law
Ardelyx tumbles as lawsuit against CMS dismissed over Xphozah (update) - MSN
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):